JP2022537555A5 - - Google Patents

Info

Publication number
JP2022537555A5
JP2022537555A5 JP2021575397A JP2021575397A JP2022537555A5 JP 2022537555 A5 JP2022537555 A5 JP 2022537555A5 JP 2021575397 A JP2021575397 A JP 2021575397A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2022537555 A5 JP2022537555 A5 JP 2022537555A5
Authority
JP
Japan
Prior art keywords
patient
smrt
ncor2
mutation
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038643 external-priority patent/WO2020257586A2/en
Publication of JP2022537555A publication Critical patent/JP2022537555A/ja
Publication of JP2022537555A5 publication Critical patent/JP2022537555A5/ja
Pending legal-status Critical Current

Links

JP2021575397A 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法 Pending JP2022537555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962864404P 2019-06-20 2019-06-20
US62/864,404 2019-06-20
US201962867172P 2019-06-26 2019-06-26
US62/867,172 2019-06-26
PCT/US2020/038643 WO2020257586A2 (en) 2019-06-20 2020-06-19 Method of treatment with viral-based gene therapy

Publications (2)

Publication Number Publication Date
JP2022537555A JP2022537555A (ja) 2022-08-26
JP2022537555A5 true JP2022537555A5 (OSRAM) 2023-06-23

Family

ID=71579659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575397A Pending JP2022537555A (ja) 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法

Country Status (5)

Country Link
US (1) US20200405883A1 (OSRAM)
EP (1) EP3986481A2 (OSRAM)
JP (1) JP2022537555A (OSRAM)
CN (1) CN114375205A (OSRAM)
WO (1) WO2020257586A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114277057B (zh) * 2021-07-09 2023-10-13 上海天泽云泰生物医药有限公司 用于治疗或预防b型血友病的重组腺相关病毒载体和方法
CN115772214B (zh) * 2022-11-30 2023-09-29 湖南家辉生物技术有限公司 F8突变体蛋白、f8基因突变体、检测f8基因突变体的引物组合、试剂及应用
WO2024151568A1 (en) * 2023-01-09 2024-07-18 Biomarin Pharmaceutical Inc. Epigenetic modifiers improve aav gene therapy durability

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EA200870130A1 (ru) 2005-12-30 2009-02-27 Мерк Патент Гмбх Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
WO2008069942A2 (en) 2006-12-05 2008-06-12 Biogen Idec Ma Inc. Novel methods of enhancing delivery of a gene therapy vector using steroids
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
EA019512B1 (ru) 2008-07-02 2014-04-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Il-6-опосредованная иммунотерапия
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR20110094307A (ko) 2008-11-13 2011-08-23 펨타 파마슈티컬스, 인크. 인간화된 항-il-6 항체
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
JP2013503919A (ja) 2009-09-08 2013-02-04 ヤンセン バイオテツク,インコーポレーテツド 癌患者においてヘプシジンを減少させるための抗il−6抗体の使用
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2016055437A1 (en) * 2014-10-06 2016-04-14 Arthrogen B.V. Aav-based gene therapy
EP3283126B1 (en) * 2015-04-16 2019-11-06 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
CA3119498A1 (en) * 2015-07-31 2017-02-09 Medimmune Limited Methods for treating hepcidin-mediated disorders
PE20181338A1 (es) * 2015-09-24 2018-08-21 Biomarin Pharm Inc Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
SG11201803654TA (en) 2015-11-03 2018-05-30 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
CN116479001A (zh) * 2015-11-13 2023-07-25 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
TWI823830B (zh) * 2015-11-13 2023-12-01 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體之病毒載體
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
WO2018129268A1 (en) * 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
TWI716668B (zh) * 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
WO2018200951A1 (en) * 2017-04-28 2018-11-01 Tran David T Multi-targeted multi-valent ligand-drug particles for the treatment and prevention of diseases and conditions
KR102386890B1 (ko) 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
MX2020002750A (es) 2017-09-13 2020-07-20 Jiangsu Hengrui Medicine Co Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
CN109867723B (zh) 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途

Similar Documents

Publication Publication Date Title
Martinet et al. Differential expression of the tumor necrosis factor/cachectin gene by blood and lung mononuclear phagocytes
Drosou et al. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses
WO2019191464A1 (en) Methods of treating ulcerative colitis
JPH10506640A (ja) C型肝炎の処置のためのリバビリンおよびインターフェロンαの使用
JPH02304027A (ja) 前新生物性病変の全身的治療のための少なくとも1種のサイトカインを含む製剤組成物の使用
JP2001515047A (ja) コンセンサスインターフェロンを使用する多発性硬化症患者の治療方法
CN113559107B (zh) 孕激素在制备抑制细胞因子风暴的药物中的应用
JP2024129140A5 (OSRAM)
JP2021534201A5 (OSRAM)
JP2024515459A5 (OSRAM)
Sauer et al. Inhibition of lipopolysaccharide-induced monocyte interleukin-1 receptor antagonist synthesis by cortisol: involvement of the mineralocorticoid receptor
Lemaitre et al. The effects of intraocular injection of interleukin-13 on endotoxin-induced uveitis in rats
JP2024531314A5 (OSRAM)
Oldham et al. The role of oxygen radicals in immune complex injury
JP2022537555A (ja) ウイルスベースの遺伝子療法による治療方法
JP2023513487A5 (OSRAM)
US20210386821A1 (en) Therapeutic composition for use in the treatment of covid-19 and other cytokine storm associated disorders
WO2025102927A1 (zh) 一种清除IgG/IgM抗体或B细胞药物的应用
JP3568208B2 (ja) 弱毒化された非免疫原性ポックスウイルスまたはパラポックスウイルスからの多種有効性パラポックス免疫誘導剤の薬剤としての使用のための新規薬効
WO2020055651A1 (en) Methods of treating psoriasis
CN115813933A (zh) Fasudil在制备治疗COVID-19引起的细胞因子风暴的药物组合物中的应用
CN119654168A (zh) 用于治疗自身免疫疾病的方法
RU2469737C1 (ru) Способ лечения хронического риносинусита
Mazuski et al. Effects of cytokine antagonists on the hepatic acute-phase response
WO2021004229A1 (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用